18889881171
Kalkine 0
countryflagUS

Aura Biosciences Inc

Healthcare US AURA

6.61USD
-0.06(0.90%)

Last update at 2025-06-13T16:45:00Z

Day Range

6.486.69
LowHigh

52 Week Range

6.6312.38
LowHigh

Fundamentals

  • Previous Close 6.67
  • Market Cap435.58M
  • Volume38676
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-91.83600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -58.76300M -35.25100M -22.20600M -24.20000M
Minority interest - - - -
Net income -57.23100M -34.42100M -22.20900M -24.20500M
Selling general administrative 18.06M 10.09M 4.16M 4.52M
Selling and marketing expenses - - - -
Gross profit -60.29500M -35.25000M - -
Reconciled depreciation 1.18M 0.83M 0.83M 0.51M
Ebit -60.29500M -35.25000M -22.20600M -24.14000M
Ebitda -59.96800M -35.23600M -21.37500M -23.63100M
Depreciation and amortization 0.33M 0.01M 0.83M 0.51M
Non operating income net other 1.53M -0.00100M - -
Operating income -60.29500M -35.25000M -22.20600M -24.14000M
Other operating expenses 60.30M 35.25M 22.21M 24.14M
Interest expense 0.85M 0.01M 0.00300M 0.00500M
Tax provision - - - -
Interest income 1.86M - - -
Net interest income 1.86M 0.01M -0.00300M -0.00500M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -1.53200M -0.83000M 0.00300M 0.00500M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 60.30M 35.25M 22.21M 24.14M
Cost of revenue 60.30M 35.25M - -
Total other income expense net 1.53M -0.00100M 0.00300M -0.06000M
Discontinued operations - - - -
Net income from continuing ops -58.76300M -35.25100M -22.20600M -24.20000M
Net income applicable to common shares -58.76300M -35.25100M -30.13200M -30.22900M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 255.07M 223.94M 160.03M 22.10M 37.05M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.62M 7.87M 4.62M 0.02M 0.06M
Total liab 29.23M 28.35M 7.71M 130.82M 124.46M
Total stockholder equity 225.85M 195.58M 152.31M -108.71300M -87.40600M
Deferred long term liab - - - - -
Other current liab 7.88M 4.57M 0.42M 0.26M 3.82M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -287.30800M -210.90000M -152.13700M -116.88600M -94.68000M
Other liab - - 0.08M 0.08M 0.10M
Good will - - - - -
Other assets 0.00000M 1.19M 0.12M 0.07M 0.07M
Cash 41.08M 121.58M 149.06M 17.39M 32.45M
Cash and equivalents - - - - -
Total current liabilities 12.36M 10.46M 7.27M 2.66M 6.15M
Current deferred revenue - - 3.83M 1.77M -
Net debt -21.52500M -100.72400M -148.08800M -17.37800M -32.40000M
Short term debt 2.69M 2.96M 0.61M 0.01M -
Short long term debt - - - 0.01M -
Short long term debt total 19.56M 20.86M 0.97M 0.01M 0.05M
Other stockholder equity 512.62M 406.56M 144.42M 8.17M 7.27M
Property plant equipment - 5.37M 5.25M 3.57M 3.63M
Total current assets 231.79M 196.70M 153.70M 18.45M 33.35M
Long term investments - - - - -
Net tangible assets - 195.58M 152.31M -108.71300M -87.40600M
Short term investments 185.09M 67.23M - - -
Net receivables - - - - -
Long term debt - - - - 0.05M
Inventory - - - - -
Accounts payable 1.79M 2.92M 2.40M 0.61M 2.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.54M -0.07200M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - -210.90000M -152.13700M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.51M 1.19M 0.12M 0.07M 0.07M
Deferred long term asset charges - - - - -
Non current assets total 23.28M 27.23M 6.33M 3.65M 3.71M
Capital lease obligations 19.56M 20.86M 0.97M - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -66.77500M -2.12500M -0.77100M -2.22100M
Change to liabilities 0.57M 3.26M -1.72100M 1.04M
Total cashflows from investing activities -67.86900M -2.12500M -0.77100M -2.22100M
Net borrowings - - -0.03400M -0.03700M
Total cash from financing activities 95.63M 166.26M 10.04M 39.73M
Change to operating activities -3.44200M -1.36900M -1.95800M 1.42M
Net income -58.76300M -35.25100M -22.20600M -24.20000M
Change in cash -26.84100M 131.72M -15.05600M 16.84M
Begin period cash flow 149.21M 17.49M 32.54M 15.70M
End period cash flow 122.37M 149.21M 17.49M 32.54M
Total cash from operating activities -54.60100M -32.41000M -24.32100M -20.66600M
Issuance of capital stock 95.20M 165.93M 9.91M 39.72M
Depreciation 1.18M 0.83M 0.83M 0.51M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 87.08M 166.27M 0.00000M -0.01300M
Other cashflows from financing activities 87.08M 87.56M 10.07M 39.78M
Change to netincome 6.09M 2.32M 0.73M 0.56M
Capital expenditures 1.09M 2.12M 0.77M 2.22M
Change receivables - - - -
Cash flows other operating -3.67600M -3.57100M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -26.84100M 131.72M - -
Change in working capital -3.10200M -0.31500M -3.67900M 2.46M
Stock based compensation 6.41M 2.31M 0.74M 0.51M
Other non cash items -0.32500M 0.00400M -0.00300M 0.04M
Free cash flow -55.69500M -34.53500M -25.09200M -22.88700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
AURA
Aura Biosciences Inc		 -0.06 0.90% 6.61 - - - 2.56 -5.6773
NVO
Novo Nordisk A/S		 -0.56 0.69% 80.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.41 0.51% 80.59 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.29 0.28% 458.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.82 0.54% 524.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Aura Biosciences Inc

80 Guest Street, Boston, MA, United States, 02135

Key Executives

Name Title Year Born
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, Pres & Director 1974
Ms. Julie B. Feder CFO, Sec. & Treasurer 1970
Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA Chief Medical Officer and Head of R&D 1965
Dr. Mark A. De Rosch Ph.D. Chief Operating Officer 1964
Mr. Paulo Carvalho VP of Technical Operations NA
Mr. Joseph Lyons VP of HR NA
Ms. Michele Keough M.B.A. Sr. VP of Project Management and Device Supply Chain NA
Dr. Elisabet de los Pinos Ph.D. Founder, CEO, President & Director 1973
Ms. Julie B. Feder CFO, Secretary & Treasurer 1970
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technology Officer 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.